
Short Title: S2312
Enrollment Status: Recruiting
NCT #: NCT06470243
Specialty Area: Oncology
Condition Studied: Metastatic Castrate-Resistant Prostate Cancer
Age Groups: Adult; Older Adult
Phase: III
This study is looking at the best way to treat prostate cancer that has spread to other parts of the body and that keeps growing even when testosterone is lowered to very low levels. Doctors call this metastatic castrate-resistant prostate cancer, or mCRPC.
Cabazitaxel is a chemotherapy drug that is already used as standard care for this type of cancer. Researchers want to find out whether adding a second chemotherapy drug, carboplatin, works better than cabazitaxel on its own. Participants receive either cabazitaxel alone or cabazitaxel together with carboplatin.
Some prostate cancers carry a set of genetic changes known as an aggressive variant signature. Tumor tissue is tested before treatment is assigned so that results can be compared between people who have this signature and people who do not. This may help doctors learn which treatment approach fits which type of cancer.
This is a phase III treatment study, which means the drugs have already been studied in smaller groups of people. Taking part may or may not help your own cancer. The main goal is to answer a question that could guide care for future patients.
This study is enrolling men who are being treated for prostate cancer that has spread. It is not enrolling healthy volunteers. The summary below describes the general requirements in everyday language.
This is not a complete list of requirements. The study team reviews your medical history, exam, and test results with you and confirms whether this trial is a good fit.
Before anything is decided, tumor tissue from an earlier biopsy is sent to a central laboratory to check for the aggressive variant signature. A chest X-ray and other baseline tests are also done to confirm you can take part.
Participants are then randomly assigned by computer to one of two treatment groups. Neither you nor your doctor chooses the group. One group receives cabazitaxel given through a vein (IV). The other group receives IV cabazitaxel together with IV carboplatin. Everyone takes prednisone by mouth twice a day.
Visits continue on the cycle schedule for as long as treatment is helping and side effects stay manageable. After treatment ends, the study team keeps in touch for follow-up visits and phone calls to check on your health and record how you are doing over time.
Taking part is voluntary. You can decide not to join, or you can stop at any point, and your regular medical care will not be affected.
Location: Renown Health, Office of Clinical Research
Address:
Complete Study Details: https://clinicaltrials.gov/study/NCT06470243
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.